Page 301 - The Vasculitides, Volume 1: General Considerations and Systemic Vasculitis

Systemic Vasculitis and the Kidney 275

[60] Vizjak A, Rott T, Koselj-Kajtna M, et al. Histologic and immunohistologic study and
clinical presentation of ANCA-associated glomerulonephritis with correlation to ANCA
antigen specificity. Am. J. Kidney Dis. 2003; 41: 539-549.

[61] Davies DJ, Moran, JE, Niall, JF, et al. Segmental necrotising glomerulonephritis with
antineutrophil antibody: possible arbovirus aetiology? Br. Med. J. (Clin .Res. Ed) 1982;
285: 606.

[62] Roth AJ, Ooi JD, Hess JJ, et al. Epitope specificity determines pathogenicity and
detectability in ANCA-associated vasculitis. J. Clin. Invest. 2013; 123:1773-1783.

[63] Cui Z, Zhao MH, Segelmark M, et al. Natural autoantibodies to myeloperoxidase,
proteinase 3, and the glomerular basement membrane are present in normal individuals.
Kidney Int. 2010; 78: 590-597.

[64] Thai LH, Charles P, Resche-Rigon M, et al. Are anti-proteinase-3 ANCA a useful
marker of granulomatosis with polyangiitis (Wegener's) relapses? Results of a
retrospective study on 126 patients. Autoimmun. Rev. 2014; 13: 313-318.

[65] Zhang J, Tian Q, Yung Chan S, et al. Metabolism and transport of oxazaphosphorines
and the clinical implications. Drug. Metab. Rev. 2005; 37:611-703.

[66] Casey, TP. Immunosuppression by cyclophosphamide in NZB X NZW mice with lupus
nephritis. Blood 1968; 32: 436-444.

[67] Many A, Schwartz RS. On the mechanism of immunological tolerance in
cyclophosphamide-treated mice. Clin. Exp. Immunol. 1970; 6: 87-99.

[68] Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in
ANCA-associated renal vasculitis. N. Engl. J. Med. 2010; 363: 211-220.

[69] Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-
associated vasculitis. N. Engl. J. Med. 2010; 363: 221-232.

[70] Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for
ANCA-associated vasculitis. N. Engl. J. Med. 2013; 369: 417-427.

[71] Smith RM, Jones RB, Guerry MJ, et al. Rituximab for remission maintenance in
relapsing ANCA-associated vasculitis. Arthritis. Rheum. 2012; 64:3760-3769.

[72] Charles P, Néel A, Tieulié N, et al. Rituximab for induction and maintenance treatment
of ANCA-associated vasculitides: a multicenter retrospective study on 80 patients.
Rheumatology 2014; 53:532-539.

[73] Pendergraft WF 3rd, Cortazar FB, Wenger J, et al. Long-Term Maintenance Therapy
Using Rituximab-Induced Continuous B-Cell Depletion in Patients with ANCA
Vasculitis. Clin J Am Soc Nephrol 2014; 9:736-744.

[74] Bunch DO, McGregor JG, Khandoobhai NB, et al. Decreased CD5+ B cells in active
ANCA vasculitis and relapse after rituximab. Clin. J. Am. Soc. Nephrol. 2013; 8: 382-
391.

[75] Gou SJ, Yuan J, Wang C, et al. Alternative complement pathway activation products in
urine and kidneys of patients with ANCA-associated GN. Clin. J. Am. Soc. Nephrol.
2013; 8: 1884-1891.

[76] Xiao H, Dairaghi DJ, Powers JP, et al. C5a Receptor (CD88) Blockade Protects against
MPO-ANCA GN. J. Am. Soc. Nephrol. 2014; 25: 225-231.

[77] Hazelwood GS, Metzler C, Tomlinson GA, et al. Non-biologic remission maintenance
therapy in adult patients with ANCA-associated vasculitis: A systematic review and
network meta-analysis. Joint Bone Spine 2014; 81:337-341.

Complimentary Contributor Copy